Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

By |2025-01-02T08:50:27-05:00December 9, 2024|Press Release|0 Comments

THANK YOU

We look forward to connecting with you